CDKN2A and neoplasm: Although several genomic studies have revealed that EGFR amplification and CDKN2A mutations are frequent somatic alterations in metastatic PSCC, their clinical significance and expression profiles during tumor progression remain elusive owing to noncomprehensive transcriptome sequencing methods, small sample sizes, and unpaired PSCC tissues [8,9,10].